XML 26 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 592,792 $ 9,724,052 $ 81,413,212 $ 55,638,769 $ 147,368,825
Beginning balance, shares at Dec. 31, 2020 592,791,712        
Contributions 791,610 4,176,800 4,968,410
Distributions (30,054,155) (8,831,693) (38,885,848)
Net loss 37,762,136 13,116,866 50,879,002
Ending balance, value at Mar. 31, 2021 $ 592,792 10,515,662 89,121,193 64,100,742 164,330,389
End balance, shares at Mar. 31, 2021 592,791,712        
Contributions 1,243,686 4,821,304 6,064,990
Distributions (30,785,270) (8,775,526) (39,560,796)
Net loss 27,059,401 2,618,644 29,678,045
Ending balance, value at Jun. 30, 2021 $ 592,792 11,759,348 85,395,324 62,765,164 160,512,628
End balance, shares at Jun. 30, 2021 592,791,712        
Beginning balance, value at Dec. 31, 2021 $ 592,792 11,742,891 102,315,623 76,929,704 191,581,010
Beginning balance, shares at Dec. 31, 2021 592,791,712        
Contributions 3,869,201 3,869,201
Distributions (27,114,936) (5,738,045) (32,852,981)
Net loss 21,442,843 3,383,288 24,826,131
Ending balance, value at Mar. 31, 2022 $ 592,792 11,742,891 96,643,530 78,444,148 187,423,361
End balance, shares at Mar. 31, 2022 592,791,712        
Beginning balance, value at Dec. 31, 2021 $ 592,792 11,742,891 102,315,623 76,929,704 191,581,010
Beginning balance, shares at Dec. 31, 2021 592,791,712        
Deconsolidation of Real Estate Entities         39,323,872
Ending balance, value at Jun. 30, 2022 $ 648,918 467,402,221 57,638,688 40,724,416 566,414,243
End balance, shares at Jun. 30, 2022 648,918,458        
Beginning balance, value at Mar. 31, 2022 $ 592,792 11,742,891 96,643,530 78,444,148 187,423,361
Beginning balance, shares at Mar. 31, 2022 592,791,712        
Reverse acquisition with Clinigence $ 50,961 446,780,842 194,747 447,026,550
Reverse acquisition with Clinigence , shares 50,961,109        
Notes payable converted to common stock $ 2,623 4,062,749 4,065,372
Notes payable converted to common stock, shares 2,622,819        
Common stock issued for exercise of warrants $ 2,147 4,116,994 4,119,141
Common stock issued for exercise of warrants , shares 2,147,252        
Common stock issued for exercise of options $ 312 644,662 $ 644,974
Common stock issued for exercise of options , shares 312,019       312,019
Restricted stock awards issued for compensation $ 83 54,083 $ 54,166
Restricted stock awards issued for compensation , shares 83,547        
Deconsolidation of Real Estate Entities (12,267,888) (27,055,984) (39,323,872)
Contributions 861,916 861,916
Distributions (7,341,202) (7,637,993) (14,979,195)
Net loss (19,395,752) (4,082,418) (23,478,170)
Ending balance, value at Jun. 30, 2022 $ 648,918 $ 467,402,221 $ 57,638,688 $ 40,724,416 $ 566,414,243
End balance, shares at Jun. 30, 2022 648,918,458